Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial

Fig. 2

The incidence and severity of adverse reactions in NVSI-06-09 booster group compared with those in BBIBP-CorV booster group. a Local adverse reactions reported within 7 days after the administration of booster vaccination. b Systemic reactions recorded within 7 days after booster vaccination. The grade of adverse reactions was determined under the guidance of China National Medical Products Administration (NMPA)

Back to article page